Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA). Opelconazole has been granted orphan drug, Fast Track, and Qualified Infectious Disease Product designations.
In December 2021, Pulmocide announced that it had received funding from The Cystic Fibrosis Foundation for development of opelconazole for the treatment of pulmonary Aspergillus infections after lung transplantation, and a Phase 2b trial of nebulized opelconazole suspension in lung transplant patients is currently underway. Earlier this year, the company also initiated a Phase 3 study of PC945 in patients with refractory IPA.
Pulmocide Chairman and CEO Daniel Burgess said, “We are thrilled with the support from both our new and existing investors in advancing Pulmocide’s mission. Together with the $95 million raised last year, we are well positioned to move opelconazole through late-stage development and to prepare to bring this potentially important new therapy to patients desperately in need of new treatment options.”
Read the Pulmocide press release.
